H.C. Wainwright analyst Edward White initiated coverage of Avalo Therapeutics (AVTX) with a Neutral rating and no price target The firm says the company’s AVTX-009 has promise to treat inflammatory diseases. The analyst waits for the initial hidradenitis suppurativa data and for the company to progress further along with the Phase 2 study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX: